Predictive Factors for the Efficacy of CD19 CAR-T Therapy in Relapsed/Refractory Large B-Cell Lymphoma: A Clinical Study

NCT07236203 · clinicaltrials.gov ↗

RECRUITING

Status

80

Enrollment

OTHER

Sponsor class

Conditions

Large B-Cell Lymphoma

Interventions

DRUG: CAR-T

Sponsor

Fudan University